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The soluble form of the b-amyloid precursor protein (sAPPa) is known to function in the autocrine regulation of
epidermal growth and repair. Here we show that its proteolytic release by a-secretase in normal human keratin-
ocytes is susceptible to hydroxamic-acid-based zinc metalloproteinase inhibitors and suppressed by these inhib-
itors by 80%–90%. As various other growth factors participate in regulating epidermal growth we investigated
whether the inhibitor-induced sAPPa-deﬁciency would affect keratinocyte proliferation. At optimal inhibitor con-
centrations the suppression of sAPPa-release was followed by a decline in proliferation by 50%–60%, indicating
that sAPPa is a major growth factor that cannot be compensated for by other growth factors. This ﬁnding was the
basis for the treatment of human lesional psoriatic keratinocytes with these inhibitors, which resulted in the
normalization of their increased proliferation rates. The reversibility of these effects and the lack of toxicity un-
derline the value of these inhibitors and suggest their therapeutic application in psoriatic skin diseases.
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Normal growth, differentiation and wound repair of the skin
are regulated by a variety of ions, cytokines and growth
factors (Martin, 1997; Fuchs and Raghavan, 2002; Werner
and Grose, 2003). Disturbances of these factors or chang-
es, particulary in the expression of growth factors may,
therefore, entail hyper- or hypotrophic skin anomalies. Al-
though the dermis participates in most diseased states of
the skin, the visible hallmarks of hyperproliferative skin dis-
eases such as psoriasis are excessive production and ex-
foliation of epidermal cells (Krueger et al, 1990). Activated T
cells appear to play a central role pointing to a primary
immunological basis of the disease. These activated T cells
are known to secrete cytokines such as interferon-g and
interleukin (IL)-2 which induce keratinocytes to proliferate
(Lebwohl, 2003). Keratinocytes, however, are able to stim-
ulate their own proliferation by an autocrine loop. This is
accomplished by the production of a variety of cytokines
and growth factors such as IL-1, IL-3, IL-6 and IL-8, trans-
forming growth factor alpha (TGFa), TGFb as well as plate-
let-derived growth factor (PDGF) (Ansel et al, 1990). The
strongly increased keratinocyte proliferation is an important
feature of psoriasis and remains, therefore, an additional
target in the therapy of the disease (Lebwohl, 2003). Les-
ional psoriatic keratinocytes are characterized by the
overexpression of a group of specific proteins including
psoriasin (Ruse et al, 2003), cytokeratins 6, 10, 16 and 17,
the antinflammatory protein SKALP/elafin (Pol et al, 2002a,
b) and TGFa (Elder et al, 1989).
Recently, the b-amyloid precursor protein (APP) has been
reported to fullfill a variety of biological purposes, including
its role as a growth factor precursor mainly for epithelial
cells including keratinocytes (Schmitz et al, 2002). Human
keratinocytes synthesize three APP isoforms of which the
isoform APP751 and APP770 are expressed at levels about
eight to 10 times above APP695 (Hoffmann et al, 2000;
Kummer et al, 2002). APP exerts a striking dual function
which is brought about by its differential cleavage leading to
the release of at least two peptides with fundamentally dif-
ferent properties: The largely insoluble Ab-peptide, the main
constituent of plaques in Alzheimer’s disease (Sisodia and
Price, 1995), is the product of the amyloidogenic cleavage
by b- and g-secretases, whereas sAPPa, the soluble N-ter-
minal portion of APP, is generated in the non-amyloidogenic
pathway by the proteolytic action of a-secretase. a-secr-
etase is a plasma membrane associated proteinase (Si-
sodia, 1992; Parvathy et al, 1999) that cleaves APP within
the Ab-sequence thereby precluding the formation of the
Ab-peptide (De Strooper and Annaert, 2000). Several mem-
bers of the ADAM (a disintegrin and metalloproteinase)
family of proteinases (Blobel, 1997) have been shown to
possess a-secretase activity, including ADAM9, ADAM10
and tumor necrosis factor-alpha convertase (TACE or AD-
AM17) (Black and White, 1998; Lammich et al, 1999). From
overexpression and knockout studies it appears that these
three enzymes, and possibly others, contribute to the
a-secretase cleavage of APP to varying extents depending
on the cell type (Allinson et al, 2003). Hydroxamic-acid-
based zinc metalloproteinase inhibitors such as Batimastat,
SB244000 and SB251626 bind to the active site of the
a-secretase and coordinate with the essential zinc ion
(Botos et al, 1996), inhibiting the cleavage of APP and
Abbreviations: APP, b-amyloid precursor protein; NBK, normal hu-
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blocking the production of sAPPa (Parvathy et al, 1998). In
neuronal cells, these inhibitors exert also effects on TNFa-
convertase and ACE-secretase (Parkin et al, 2002), which,
however, appear to be absent from keratinocytes.
In keratinocytes and epidermal wound healing model
systems, increased expression of APP and release of
sAPPa are followed by elevated rates of proliferation
(Kummer et al, 2002). Because sAPPa can be regarded as
a major epidermal growth factor, inhibition of its release
would be a promising approach for studies on its role in the
regulation of pivotal keratinocyte functions.
In this report, we show that in psoriatic epidermis the
expression of APP is not limited to the basal cell layer and is
also observed in supra-basally located cells suggesting that
inhibition of a-secretase activity might have a particularly
strong effect on psoriatic epidermis. We have, therefore,
analyzed the inhibition of a-secretase and its effect on ker-
atinocyte proliferation in cell culture and in a newly devel-
oped epidermal organ culture system. The results show that
keratinocyte proliferation is significantly reduced when Bat-
imastat or other structurally related inhibitors are applied
and that this effect is directly linked to suppressed sAPPa-
secretion. Because these effects are reversible and the in-
hibitors do not exert detectable toxic effects on cells they
are valuable tools for experiments in which the deficiency of
endogenous sAPPa is required. Due to the strong prolifer-
ation-reducing effect on psoriatic keratinocytes, the inhibi-
tion of a-secretase is of potential therapeutical use.
Results
In this study, the proteolytic release of sAPPa from APP and
the effects of a-secretase inhibitors were determined. Re-
combinant sAPPa751 (rec-sAPPa751; Fig 1a) was prepared,
purified (Fig 1b) and applied to compensate for the inhibitor
induced sAPPa-deficiency and its consequences on kera-
tinocyte proliferation. Two distinct in vitro systems were
employed, the cell culture of keratinocytes, using human
adult low calcium, high-temperature keratinocytes (HaCaT)
cells, normal human keratinocytes (NHK), isolated human
breast skin keratinocytes (NBK) as well as lesional psoriatic
keratinocytes (PK) and the organ culture of isolated human
epidermis.
Inhibition of sAPPa-release without effects on the ex-
pression of full-length APP Optimal concentrations of the
hydroxamic-acid-based zinc metalloproteinase inhibitors at
which the release of sAPPa by keratinocytes was efficiently
inhibited but toxic side effects were excluded were deter-
mined. Necrotic cells were marked with propidium iodide
whereas apoptotic cells were detected by the binding of
Annexin-V to phosphatidyl serine. The presence of up to
100 mM of inhibitor in the culture medium of HaCaT and
NHK’s after 7 h revealed neither an effect on the number of
necrotic cells nor of apoptotic cells (data not shown).
Analysis of the APP expression in cell lysates revealed
that none of the inhibitors had any effect on the expression
of APP as shown for the amount of mature or immature APP
(Fig 2a). The small proportion of total cellular APP residing in
the plasma membrane (Selkoe, 1999), where most of the
sAPPa-release is known to occur, explains why the inhibi-
tion of sAPPa-release did not result in a detectable increase
of total cellular APP levels.
The application of the inhibitors caused a suppression of
sAPPa-release into the culture medium in a concentration-
dependent manner reaching strong inhibition at 20 mM
(shown for HaCaT cells) (Fig 2a). Quantitation of this inhib-
itory effect revealed that all inhibitors significantly sup-
pressed the release of sAPPa at concentrations of 20 mM by
about 80% (Fig 2b) or up to 90% (Fig 2d). At 30 mM, com-
plete inhibition was observed. To use the lowest possible
concentration resulting in sufficient inhibition, however, all
subsequent experiments were performed at inhibitor con-
centrations of 20 mM. At this concentration highest inhibition
was reached at 7 h after the addition of the respective
inhibitor (Fig 2c, d).
Reversibility of the inhibitory effect To investigate the
duration of the inhibitory effect on sAPP-release, keratin-
ocytes were incubated in the presence of 20 mM of each
one inhibitor for various periods of time. The densitometric
analysis of the immunoblots indicated that the effect of each
of the three inhibitors on the sAPPa-release lasted for about
24 h. After this period the a-secretase activity was regained
and at 48 h the sAPPa-release increased to 20%–60% (here
shown for HaCaT cells) (Fig 2c, d) and at 72 h to 40%–90%
of the original levels (not shown). The inhibitory periods
were prolonged when inhibitors were replenished again
after 24 h of incubation (data not shown).
Inhibitor induced suppression of keratinocyte prolifer-
ation and re-establishment by exogenously added
rec-sAPPa751 The proportion of proliferation competent
keratinocytes was determined immunocytochemically by
Figure1
Preparation of recombinant sAPPa (rec-sAPPa751). (a) structure of
recombinant sAPPa (rec-sAPPa751) carrying a His-tag (blue) for puri-
fication purposes. The scheme depicts also the distribution of the three
heparin-binding sites (HBS, green), the Kunitz-type serine proteinase
inhibitor domain by which it is distinguished from sAPP695 (KPI, black)
and the putative proliferation-stimulatory region (Jin et al, 1994) (yel-
low). (b) Coomassie blue stained SDS gel of recombinant sAPPa751,
indicating the purity of the preparation.
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the Ki67-assay (here shown for HaCaT cells) (Fig 3a). A sig-
nificant reduction of Ki67 positive proliferation competent
cells as compared to controls was observed after incuba-
tion in the presence of 20 mM of each one inhibitor for 48 h.
Maximum decrease in the proliferation rate was observed at
24 h, i.e., 17 h after maximum inhibition of sAPPa-release
occurred.
Optimal proliferation stimulating effects were found to be
at 10 nM rec-sAPPa751 in the absence and the presence of
20 mM of each one inhibitor (Fig 3b). The dose–response
curve for cells in which the release of sAPPa was blocked
by the inhibitor showed a stronger increment as compared
to values without inhibitor. The rates of proliferation of cells
in the absence of the inhibitor decreased at rec-sAPPa751
concentrations above 10 nM as described before (Hoff-
mann et al, 2000). The dose–response curve in the presence
of the inhibitor showed a similar decline. The reduction in
proliferation of keratinocytes after treatment with the inhib-
itors (here SB244000) was overcome by the addition of rec-
sAPPa751 (Fig 3c). These results showed that sAPPa was
indeed the growth-promoting agent. Moreover, the full re-
versibility of inhibition strongly argues against the occur-
rence of toxic side effects.
There was a clear sequence of events with maximum
inhibition of sAPPa-release at 7 h (see Fig 2d), maximum
reduction of keratinocyte proliferation was observed at 24 h
(see Fig 3a) after addition of the respective inhibitors and
complete compensation by exogenously added rec-sAP-
Pa751 (Fig 3d). The difference of 17 h between both events
corresponds to previous observations of sAPPa-induced
proliferation which is noted after a period of about this
length (Hoffmann et al, 2000).
To detect whether the reduced proliferation in the pres-
ence of the inhibitors was also detectable in keratinocytes
in situ, epidermis from surgically removed normal female
breast skin was cultured for 48 h in the absence or presence
of 20 mM of each one of the inhibitors. The epidermal struc-
ture (Fig 4a), particularly that of the basal cell layer remained
intact as shown by the immunocytochemical detection of
b1-integrin (Fig 4b). The number of proliferation competent
keratinocytes in whole-mount preparations as shown by
immunocytochemical visualization of Ki67 (Fig 4c, d) was
significantly reduced in the presence of each of the inhib-
itors, shown for SB244000 (Fig 4d), but regained former
levels after the addition of 10 nM rec-sAPPa751. When such
epidermal preparations were incubated in the presence of
[3H]thymidine, the incorporation was clearly diminished af-
ter application of the inhibitors and re-established following
the addition of rec-sAPPa751 (Fig 4e).
Effect of the inhibitors on the expression of APP and
the release of sAPPa in lesional psoriatic keratino-
cytes Comparison of immunocytochemical sections of nor-
mal human breast and lesional psoriatic skin revealed that
in lesional psoriatic skin the APP-expression was not re-
stricted to the basal cell layer as shown for normal human
breast skin (Fig 5a) but located also in supra-basal cell lay-
ers (Fig 5b). Thus, the APP-expression and, presumably,
also the sAPPa-release was strongly increased in lesional
psoriatic as compared to normal human breast epidermis
(Fig 5c). In contrast, APP-expression did not differ signifi-
cantly in isolated keratinocytes from normal human breast
(Fig 5d) and lesional psoriatic (Fig 5e) skin, indicating that
the amount of APP per single cell was nearly the same in
both healthy and lesional psoriatic keratinocyte subtypes.
Similar to HaCaT cells (Fig 2), NHK or NBK (Fig 5d) the
release of sAPPa by PK’s was significantly reduced after 7 h
at 20 mM of each one of the inhibitors (here Batimastat),
whereas the expression of APP remained constant (Fig 5d,
e). The PK’s differed from NBK’s in that they showed an
early recovery of the sAPPa-release after 24 h, already.
Proliferation rates of lesional psoriatic keratinocytes Due
to the pronounced papillary structure of lesional psoriatic
skin (Fig 5b), whole-mount cultures of the epidermis were
not suitable to determine the proliferation rates by the
immunocytochemical Ki67-, BrdU- or the radiochemical
Figure 2
Effect of inhibitors on the expression of APP and the release of
sAPPa. (a, b) HaCaT cells were incubated either in the absence or
presence of various inhibitor concentrations for 7 h or (c, d), in the
presence of 20 mM for various periods of time as indicated. (a)
immunoblot analyses (here shown for SB244000) revealed that the ex-
pression of APP remained unchanged whereas (b), sAPPa decreased
significantly by about 80% for all three inhibitors. (c, d) Maximum in-
hibition of sAPPa-release was observed at 7 h. The inhibitory effect
lasted for about 24 h followed by the recovery of sAPPa-release. Sim-
ilar effects were observed in NHK (not show) and NBK’s (compare with
Fig 5). (n¼3; po0.05).
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[3H]-thymidine-assays. This made necessary the establish-
ment of lesional psoriatic keratinocyte cultures which re-
quired greater care than that of NBK’s. Despite optimal
conditions in keratinocyte growth medium (KGM)-2 and the
avoidance of all centrifugation steps, 40% of all psoriatic
cultures did not survive. All successful cultures, however,
maintained their highly increased proliferation rates and the
typical cytokeratin expression for at least three passages.
Thus PK’s exhibited a highly elevated expression of CK5, 6
and 10 which were barely detectable in NBK’s (Fig 6a),
whereas CK18 was equally expressed in both systems. The
immunocytochemical detection of proliferation competent
keratinocytes by the Ki67- and BrdU-assays revealed that in
contrast to NBK’s the proliferation of PK’s remained in-
creased about threefold when transferred to normal culture
medium (Fig 6b).
After 24 h of incubation in the presence of 20 mM of each
one of the inhibitors (shown for Batimastat, BrdU-assay),
the proliferation rate was significantly reduced by  50%
thereby reaching the proliferation rates of NBK. The reduc-
tion in proliferation was completely compensated for in NBK
and by 70% in PK by the addition of rec-sAPPa751 (Fig 6c).
The proportion of proliferation competent cells was greater
in cultured lesional psoriatic than in NBK’s (not shown). This
may explain why the inhibitors exerted their effect on more
lesional psoriatic than on normal keratinocytes. Indirect re-
duction of sAPPa-release by antisense inhibition of APP-
expression was comparable to the inhibition of a-secretase
in NBK’s but less efficient in PK’s reaching 60% of control
values (data not shown).
Discussion
Inflammatory cells such as activated T cells are known to be
involved in the manifestation of psoriasis (Ghoreschi et al,
2003; Lebwohl, 2003), whereas the notion that keratin-
ocytes themselves also contribute to their enhanced
Figure 3
Suppressed proliferation in the presence of
inhibitors. (a) the proliferation of HaCaT cells as
analyzed with the Ki67-assay showed strongly
reduced proliferation rates after incubation with
20 mM of the respective inhibitor for 48 h. (b)
Dose–response curve for rec-sAPPa751 in the
absence or presence of 20 mM of each one in-
hibitor. Optimal proliferation stimulating effects
for both conditions were observed at 10 nM rec-
sAPPa751. (c) Re-establishing normal rates of
proliferation by exogenously added rec-sAP-
Pa751. After addition of 10 nM rec-sAPPa751,
both the cells incubated in the presence of an
inhibitor and the controls showed a significant
increase of the proliferation rate. (d) Maximum
inhibition of sAPPa-release was at  7 h where-
as maximum reduction of keratinocyte pro-
liferation was at  24 h. The suppression of
keratinocyte proliferation was compensated for
by the addition of rec-sAPPa751. (n¼ 9;, signif-
icant to control; #, significant to the samples
without sAPPa; po0.05).
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proliferation rate is not uniformly supported (Kadunce and
Krueger, 1995). Indeed, initial studies on cultured keratin-
ocytes from lesional psoriatic skin failed to demonstrate
enhanced proliferation (Krueger et al, 1981; West et al,
1983). Recent investigations including this study showed,
however, that such keratinocytes sustain their characteristic
psoriatic expression pattern and their hyperproliferative
phenotype in vitro for at least three passages of culture
(Harper et al, 1978; Staiano-Coico et al, 1987; Van Ruissen
et al, 1996; Buisson-Legendre et al, 2000). As keratinocyte
growth is strongly stimulated by sAPPa, the primary aim of
this study was to elucidate the role of inhibitors of sAPPa-
release on the proliferation of normal and lesional psoriatic
keratinocytes.
Advantage of a-secretase inhibition above existing
procedures Our study shows that hydroxamic-acid-based
zinc metalloproteinase inhibitors can be applied at optimal
concentrations of 20 mM to epidermal organ- and keratin-
ocyte-cultures for prolonged periods of time without toxic
side-effects and that this application results in an inhibition
of sAPPa-release by about 80%–90%. As a-secretases are
known to cleave all members of the APP protein family in-
cluding the APP homologues APLP1 (Paliga et al, 1997) and
APLP2 (Slunt et al, 1994), their inhibition is superior to the
knockout of an APP isoform or the blocking by antisense
procedures. This view is supported by the observation that
the expression of APP is not suppressed by the inhibitors
and that total cellular APP accumulation does not increase
despite the suppressed a-secretase cleavage. After about
48 h of incubation however, in the presence of each of the
inhibitors, the constitutive release of sAPPa is partially re-
stored. As the replenishment of the inhibitors shortly before
the end of this period prolonged the inhibition of sAPPa-
release, it can be assumed that with time the inhibitor con-
centrations decrease due to degradation or irreversible
binding to the a-secretase and clearance, e.g., by end-
ocytosis. Judging by the efficient block of sAPPa-release
the inhibitors appear to be most suitable experimental tools
to efficiently hamper cell-type specific functions of sAPPa.
Normalization of keratinocyte proliferation as an addi-
tional anti-psoriatic treatment Presumed key regulators
of keratinocyte proliferation include PDGF, EGF (Nanney
et al, 1996), TGFa from basal keratinocytes (Rappolee et al,
1988; Nanney et al, 1996), KGF from dermal fibroblasts
(Werner et al, 1992) and activin (Munz et al, 1999). Inhibition
of these growth factors or blockade of receptor signaling,
however, revealed that none of these factors is absolutely
essential for epidermal growth (Grose and Werner, 2002). In
contrast, although numerous other factors contribute to the
regulation of keratinocyte proliferation (Martin, 1997; Fuchs
and Raghavan, 2002), the almost complete block of sAPPa-
release results in a significant reduction in the proliferation
rates in both keratinocyte- and epidermal organ cultures by
50%–60%. Recent observations have shown that the pro-
liferation rates of keratinocytes from non-lesional psoriatic
skin are between the rates of keratinocytes from lesional
psoriatic and normal skin (unpublished observations). The
higher proliferation rates characteristic of PK’s are reduced
to approximately normal levels following the inhibition of
a-secretase. Hence, cytokines and other epidermal growth
factors synthesized and released by keratinocytes such as
TGFa (Barrandon and Green, 1987; Elder et al, 1989) can
compensate only partially for the lack of sAPPa. The finding
that other growth factors are unable to fully make up for the
sAPPa deficiency is novel and the basis for the in vitro
treatment of PK’s with these inhibitors. Some growth factors
are known to be highly expressed in lesional psoriatic ker-
atinocytes such as TNFa (Ansel et al, 1990; Gro¨ne, 2002),
TGFa (Elder et al, 1989), heparin binding EGF and amp-
hiregulin (Cook et al, 1992; Piepkorn, 1996). The release
of these growth factors might be sensitive to metal-
loproteinase inhibitors as well (Piepkorn et al, 1998). The
inhibition of their release might account for the incomplete
compensation of lesional psoriatic keratinocyte proliferation
by rec-sAPPa751. The less efficient reduction in the prolif-
eration rate of PK using the specific inhibition of APP-
expression by antisense constructs supports this possibility.
Figure 4
Inhibitor effects on keratinocyte proliferation in epidermal organ
culture. Light microscope analyses revealed that the basal cell layer
(arrows) of isolated epidermis remained intact (a), paraffin section
stained with hematoxylin and eosin and (b) whole-mount preparation,
visualization of b1-integrin as a marker of basal cells). (c, d) proliferation
competent keratinocytes as visualized by the detection of Ki67. (d) The
number of proliferation competent cells was reduced when cells were
cultured in the presence of 20 mM of each inhibitor for 48 h (here shown
for SB244000) as compared to controls (c) and compensated for by the
addition of rec-sAPPa751 (not shown). (e) Quantitation by the [
3H]thy-
midine assay confirmed the low proliferation rate in the presence of the
inhibitors and the reversal of this process by rec-sAPPa751. (Scale
bar¼ 20 mm; n¼3; po0.05.)
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The three inhibitors differ considerably in length and
composition of their side chains (Gearing et al, 1994), but no
significant differences exist in their inhibitory effects on
sAPPa-release and on keratinocyte proliferation. Differenc-
es may exist, however, in the recovery of suppressed
sAPPa-release with Batimastat showing prolonged periods
of suppression. The lack of major differences in their spe-
cific function allows to select the most suitable inhibitor for
its ability to reach the basal epidermal cell layer. The de-
crease in proliferation can be effectively overcome by
exogenously added rec-sAPPa751, supporting our view that
the inhibitory proliferation rates indeed result from the
strongly suppressed sAPPa-secretion and that toxic side
effects do not occur. This is important as long-term safety
and tolerability are major selection criteria for optimal an-
tipsoriatic therapies.
Methods are being developed to apply these inhibitors to
the epidermis in situ. In further experiments, nude mice
transplanted with lesional psoriatic skin will allow to study in
detail the effects of the inhibitors in an in vivo model system.
The most successful existing therapies for psoriasis in-
clude photochemotherapy (Zanolli, 2003) as well as met-
hotrexate (Heydendael et al, 2003) and immunomodulatory
treatment (Asadullah et al, 2002). Our results suggest an
additional therapeutic approach in the treatment of psoriatic
skin diseases by the application of hydroxamic-acid-based
zinc metalloproteinase inhibitors.
Materials and Methods
Material Biopsies of lesional skin of five psoriatic patients (aged
between 27 and 78 years) were taken under local anesthesia after
obtaining informed consent. The patients suffered from clinically
and histopathologically confirmed psoriasis and were left without
treatment for at least 4 wk. Experimentation with human tissue
samples was conducted in accordance with the ethical principles
and guidelines of the Medical Faculty of the University of Bonn
as approved by the governmental authorities. Hydroxamic-acid-
based zinc metalloproteinase inhibitors (Batimastat, SB244000,
SB251626), were kindly provided by GlaxoSmithKline-Pharmaceu-
ticals (Harlow, UK). APP synthesis was specifically inhibited by the
preparation and application of antisense constructs as previously
described (Hoffmann et al, 2000). The secondary antibodies were
Figure 5
Effect of inhibitors on APP-expression and sAPPa-release in lesional psoriatic keratinocytes. (a, b) Immunocytochemical detection of APP
(green) and laminin-5 (red) displayed the localization of APP to the basal cell layer in normal human breast skin (a) and to the basal and supra-basal
cell layers of lesional psoriatic skin (b). (c) Immunoblot analysis of APP in the epidermis isolated from normal human breast and lesional psoriatic
skin. Quantitation revealed an about threefold higher amount of APP in lesional psoriatic epidermis (not shown). (d, e) Immunoblot analysis of NBK’s
(d) and PK’s (e) showed a significant decrease of sAPPa-release after 7 h at 20 mM inhibitor (shown for Batimastat), but an early recovery of sAPPa-
release of PK’s after 24 h (e) as compared to NBK’s (d). As also shown in (d) and (e), the APP-expression remained unchanged. (Scale bar in a and b,
200 mm; n¼ 5.)
Figure 6
Effect of inhibitors on the proliferation of lesional psoriatic kera-
tinocytes. (a, b) The characteristic properties of cultured PK’s were
maintained for at least three passages as shown by the elevated ex-
pression of cytokeratins 5, 6 and 10 (a) and the threefold increase of the
proliferation rate of PK’s marked with BrdU (b) as compared to NBK’s.
(c) the quantitation of the BrdU-assay revealed a normalization of the
proliferation rate of PK’s after 24 and 48 h reaching the values of
keratinocytes from normal human breast skin. By the addition of
exogenous rec-sAPPa751, the suppression of proliferation was com-
pensated for reaching values slightly above the controls in NBK but
only 70% of control values in PK (n¼5; po0.05).
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from Dianova (Hamburg, Germany). Recombinant sAPPa (rec-
sAPPa751) was prepared as described (Popp et al, 1996) using
EBNA293 cells and the cDNA of APP751.
Culture of human epidermis Human skin (Dr K. Jaeger, Marien-
hospital, Bru¨hl, Germany) was digested with 10 mg per mL di-
spase-II (Roche Molecular-Biochemicals, Mannheim, Germany) in
KGM (BioWithaker, Verveirs, Belgium) without EGF/BPE (KGM) for
15 h at 41C, before epidermis and dermis were separated. For
organ culture, the epidermal sheets were placed on porous poly-
carbonate membranes (3 mm pore size) of tissue culture inserts
(Nunc, Naperville, Illinois) and cultured in KGM, which allowed ‘‘air-
exposed’’ culture. To visualize the structure of normal and psoriatic
skin and to test the preservation of isolated epidermis 5 mm sec-
tions were stained with hematoxylin and eosin.
Cell culture In all experiments, three keratinocyte cell-culture
systems were used. HaCaT cells cultured in Dulbecco’s minimal
essential medium (DMEM; BioWithaker) containing 10% fetal calf
serum (FCS), NHK obtained from BioWithaker and isolated NBK
(Leigh et al, 1994) cultured in KGM. In all studies, the cells were
cultured during the experiments in serum-free DMEM (DMEM) or
KGM. Keratinocytes from lesional psoriatic skin biopsies were
prepared by the same technique. Care was taken that the dermal
papillae remained intact which was controlled by scanning electron
microscopy (not shown). Lesional psoriatic keratinocytes (PK) were
cultured in KGM-2 (BioWithaker) containing 10% FCS. 48 h later
the medium was replaced by serum-free medium, which was
changed every two days. Under these conditions, PK’s maintained
their high proliferation rates and their characteristic overexpression
of different cytokeratines (monoclonal cytokeratine 5, 6, 10 and 18
antibodies were from Chemicon, International, Hofheim, Germany).
Because of the decline of the hyperproliferative characteristics of
PK’s after multiple passages all experiments were performed after
the second or third passage.
Proliferation assays To determine the proliferation rate the cul-
ture of HaCaTcells, NHK, NBK, PK or epidermal organ culture were
performed as described above. After the respective incubations,
the cells were stained either with the monoclonal anti-Ki67 anti-
body (DAKO, Hamburg, Germany) or after BrdU-incorporation
(Gratzner, 1982) with the monoclonal anti-BrdU antibody (Roche-
Diagnostics GmbH, Mannheim, Germany) and viewed with a flu-
orescence microscope (Axiophot, Zeiss, Jena, Germany). The
proliferation index was calculated from the ratio of the Ki67- or
BrdU-positive cells and the total number of cells marked with
propidium iodide (2 mg per mL in anti-fade reagent; Biomeda Cor-
poration, Foster City, California). For morphometric quantitation,
the imaging software ImageProPlus (Media Cybernetics, Silver
Spring, Maryland) was used. The integrity of basal cells was
determined by the monoclonal antibody P5D2 against b1-integrin
(Chemicon).
[3H]thymidine-incorporation assay Human epidermis was cut
into equal pieces using a 6 mM biopsy punch (pfm GmbH, Co-
logne, Germany) and placed on membranes of tissue culture in-
serts (Nunc). For the last three hours of incubation 20 mCi per mL
[3H]thymidine (Amersham-Bioscience, Little Chalfront, UK) was
added to the medium (DMEM). The epidermal sheets, together
with the membrane, were cut out using an 8 mM biopsy punch,
washed and transferred into vials with scintillation cocktail (Lumac-
LSC B.V., Groningen, The Netherlands). The radioactivity was de-
termined in a TriCarbb-scintillation counter (Packard, Burhard,
Germany).
Immunoelectrophoretic blot analysis To analyze the expression
of APP in keratinocytes and the sAPPa-release into culture medi-
um, cell lysates and media, concentrated 50-fold (Centricon tubes;
Amicon, Bredford, MA), were run on a 10% polyacrylamide SDS-
gel and blotted onto a nitrocellulose-membrane (Protan-Nitrocel-
lulose, Schleicher-Schuell, Dassel, Germany). Subsequently the
proteins were detected using the rabbit anti-APP antiserum 2189,
raised as described (Popp et al, 1996), or the monoclonal anti-
sAPPa antibody 1560 (Chemicon), visualized by chemilumines-
cence (ECL, Amersham, Braunschweig, Germany), documented
on XAR-5 films (Kodak, Stuttgart, Germany) and evaluated by dig-
ital image analysis.
Immunocytochemistry Cryostat sections, 7 mm thick, of cultured
epidermis were stained with the rabbit anti-APP antiserum 2189
and the monoclonal anti-human epiligrin (laminin-5) antibody
MAB1949 (Chemicon). Sections were viewed with an LSM510
(Zeiss).
Statistical analysis The results were analyzed for statistical dif-
ferences between the groups by a one-way ANOVA. In general, the
differences were taken to be statistically significant at po0.05.
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